Daiichi Sankyo (OTCMKTS:DSNKY) Sees Strong Trading Volume – Here’s What Happened

Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw unusually-strong trading volume on Wednesday. Approximately 804,812 shares were traded during mid-day trading, an increase of 164% from the average daily volume of 304,809 shares. The stock last traded at $18.80 and had previously closed at $18.15.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on DSNKY shares. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research cut shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce”.

Daiichi Sankyo Price Performance

The firm has a fifty day moving average price of $17.77 and a two-hundred day moving average price of $17.63. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $35.04 billion, a P/E ratio of 19.19, a P/E/G ratio of 2.08 and a beta of -0.10.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.08. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. The company had revenue of $3.77 billion for the quarter, compared to analysts’ expectations of $3.58 billion. On average, analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 EPS for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.